Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) Short Interest Down 38.4% in July

Posted by Jeff Wilder on Jul 30th, 2026

Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC – Get Free Report) was the target of a significant drop in short interest in the month of July. As of July 15th, there was short interest totaling 51,582 shares, a drop of 38.4% from the June 30th total of 83,765 shares. Based on an average daily volume of 36,650 shares, the days-to-cover ratio is presently 1.4 days. Approximately 5.2% of the company’s stock are sold short.

Virtus LifeSci Biotech Clinical Trials ETF Trading Up 3.8%

Shares of BBC stock traded up $1.84 during trading on Thursday, reaching $50.27. The company’s stock had a trading volume of 13,780 shares, compared to its average volume of 24,128. Virtus LifeSci Biotech Clinical Trials ETF has a 1-year low of $20.87 and a 1-year high of $54.95. The stock’s 50-day moving average price is $47.55 and its 200 day moving average price is $44.19.

Institutional Investors Weigh In On Virtus LifeSci Biotech Clinical Trials ETF

An institutional investor recently bought a new stake in Virtus LifeSci Biotech Clinical Trials ETF stock. Worth Asset Management LLC purchased a new stake in Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC – Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 4,093 shares of the company’s stock, valued at approximately $216,000. Worth Asset Management LLC owned approximately 0.41% of Virtus LifeSci Biotech Clinical Trials ETF at the end of the most recent reporting period.

About Virtus LifeSci Biotech Clinical Trials ETF

(Get Free Report)

The Virtus LifeSci Biotech Clinical Trials ETF (BBC) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials. BBC was launched on Dec 16, 2014 and is managed by Virtus.